Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases

Neuroendocrinology Letters

Volumn 32, Issue SUPPL. 1, 2011, Pages 57-70

  Martinek, Vaclav ^a   Kubickova, Bozena ^a   Arlt, Volker M ^b   Frei, Eva ^c   Schmeiser, Heinz H ^c   Hudecek, Jiri ^a   Stiborova, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Acetyltransferase; Aristolochic acid; DNA adducts; Molecular modeling; NAD(P)H:quinone oxidoreductase; Sulfotransferase

Indexed keywords

ACYLTRANSFERASE; ARISTOLOCHIC ACID; ARISTOLOCHIC ACID 1; ARISTOLOCHIC ACID 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DNA BINDING; ENZYME ACTIVATION; HUMAN; LIVER CYTOSOL; MOLECULAR DOCKING;

EID: 84857387612     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Arlt VM (2005) 3-Nitrobenzanthrone, a potential human cancer hazard in diesel exhaust and urban air pollution: a review of the evidence. Mutagenesis 20: 399-410.
2. Arlt VM, Ferluga D, Stiborova M, Pfohl-Leszkowicz A, Vukelic M, Ceovic S, et al. (2002a) Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 101: 500-502.
3. Arlt VM, Stiborova M and Schmeiser HH (2002b) Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17: 265-277. (Pubitemid 34814645)
4. Arlt VM, Stiborova M, vom Brocke J, Simoes ML, Lord GM, Nortier JL, et al. (2007) Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 28: 2253-2261. (Pubitemid 350111583)
5. Arlt VM, Stiborova M, Henderson CJ, Osborne MR, Bieler CA, Frei E, et al. (2005) Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H: quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res 65: 2644-2652. (Pubitemid 40490063)
6. Arlt VM, Zuo J, Trenz K, Roufosse CA, Lord GM, Nortier JL, et al. (2011) Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int J Cancer 128: 21-32.
7. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18: 1063-1067.
8. Cavelier G and Amzel LM (2001) Mechanism of NAD(P)H: quinone reductase: Ab initio studies of reduced flavin. Proteins 43: 420-432. (Pubitemid 32476438)
9. Chan W, Luo HB, Zheng Y, Cheng YK and Cai Z (2007) Investigation of the metabolism and reductive activation of carcinogenic aristolochic acids in rats. Drug Metab Dispos 35: 866-874. (Pubitemid 46798597)
10. Cleland WW (1983) Statistical analysis of the enzyme kinetic data. Methods Enzymol 63: 103-138.
11. Debelle FD, Vanherweghem JL and Nortier JL (2008) Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74: 158-169. (Pubitemid 351915079)
12. Faig M, Bianchet MA, Talalay P, Chen S, Winski S, Ross D, et al. (2000) Structures of recombinant human and mouse NAD(P)H: quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc Natl Acad Sci USA 97: 3177-3182. (Pubitemid 30183275)
13. Faig M, Bianchet MA, Winski S, Hargreaves R, Moody CJ, Hudnott AR, et al. (2001) Structure-based development of anticancer drugs: complexes of NAD(P)H: quinone oxidoreductase 1 with chemotherapeutic quinines. Structure 9: 659-667. (Pubitemid 32772888)
14. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, et al. (2003) Gaussian 03, Gaussian, Inc., Wallingford, CT.
15. Glatt H (2000) Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact 129: 141-170.
16. Glatt H, Boeing H, Engelke CEH, Kuhlow LMA, Pabel U, Pomplun D, et al. (2001) Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat Res 482: 27-40. (Pubitemid 32787079)
17. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, et al. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 104: 12129-12134. (Pubitemid 47185641)
18. Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, et al. (2009) A review of human carcinogens-Part A: pharmaceuticals. Lancet Oncol 10: 13-14.
19. Hein DW (2002) Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 506-507: 65-77.
20. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9: 29-42. (Pubitemid 30062907)
21. Huey R, Morris G M, Olson AJ and Goodsell DS (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28: 1145-1152. (Pubitemid 46506716)
22. Kohara A, Suzuki T, Honma M, Ohwada T and Hayashi M (2002) Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (MutaMouse). Mutat Res 515: 63-72. (Pubitemid 34242933)
23. Lai MN, Wang SM, Chen PC, Chen YY and Wang JD (2010) Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 102: 179-186.
24. Lemy A, Wissing KM, Rorive S, Zlotta A, Roumeguere T, Muniz Martinez MC, et al. (2008) Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis 51: 471-477. (Pubitemid 351273477)
25. Li R, Bianchet MA, Talalay P and Amzel LM (1995) The three-dimensional structure of NAD(P)H: quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: Mechanism of the two-electron reduction. Proc Natl Acad Sci USA 92: 8846-8850.
26. Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G and Pusey CD (2001) Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358: 1515-1516. (Pubitemid 33055708)
27. Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T et al. (2004) DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 43: e11-17.
28. Mei N, Arlt VM, Phillips DH, Heflich RH and Chen T (2006) DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat Res 602: 83-91. (Pubitemid 44693560)
29. Meinl W, Pabel U, Osterloh-Quitroz H, Hengstler JG and Glatt H (2006) Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int J Cancer 118: 1090-1097. (Pubitemid 43185594)
30. Nedelko T, Arlt VM, Phillips DH and Hollstein M (2009) TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer 124: 987-990.
31. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342: 1686-1692. (Pubitemid 30354515)
32. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis 11: 1627-1633.
33. 32P-postlabeling assay for DNA adducts. Nature Prot 2: 2772-2781.
34. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A and Siegel D (2000) NAD(P)H: quinone oxidoreductase (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms, Chem-Biol Interact 129: 77-97. (Pubitemid 32061055)
35. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C and Cosyns JP (1996) Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 56: 2025-2028. (Pubitemid 26119902)
36. 32P-postlabelling: evidence for reductive activation by peroxidase. Carcinogenesis 18: 1055-1962.
37. Schmeiser HH, Pool BL and Wiessler M (1984) Mutagenicity of the two main components of commercially available carcinogenic aristolochic acid in Salmonella typhimurium. Cancer Lett 23: 97-101. (Pubitemid 14088800)
38. Schmeiser HH, Schoepe K-B, and Wiessler M (1988) DNA adduct formation of aristolochic acidI and II in vitro and in vivo. Carcinogenesis 9: 297-303. (Pubitemid 18037995)
39. Schmeiser HH, Stiborova M and Arlt VM (2009) Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr Opin Drug Discov Devel 12: 141-148.
40. Shibutani S, Dong H, Suzuki N, Ueda S, Miller F and Grollman AP (2007) Selective toxicity of aristolochic acids I and II. Drug Metab Dispos 35: 1217-1222. (Pubitemid 46956445)
41. Simoes ML, Hockley SL, Schwerdtle T, da Costa GG, Schmeiser HH, Phillips DH et al. (2008) Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53. Toxicol Appl Pharmac 232: 86-98.
42. Sistkova J, Hudecek J, Hodek P, Frei E, Schmeiser HH and Stiborova M (2008) Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. Neuro Endocrinol Lett 29: 733-737.
43. Smith G, Stanley LA, Sim E, Strange RC and Wolf R (1995) Metabolic polymorphism and cancer susceptibility. Cancer Surveys 25: 27-65.
44. Stiborova M, Asfaw B and Anzenbacher P (1988) Activation of carcinogens by peroxidase. Horseradish peroxidase-mediated formation of benzenediazonium ion from a non-aminoazo dye, 1-phenylazo-2-hydroxynaphthalene (Sudan I) and its binding to DNA. FEBS Lett 232: 387-390.
45. 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 15: 1187-1192.
46. Stiborova M, Frei E, Arlt VM and Schmeiser HH (2008a) Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res 658: 55-67. (Pubitemid 351172880)
47. 32P-postlabeling analysis of DNA adduct formation. Mutat Res 493: 149-160.
48. Stiborova M, Frei E, Hodek P, Wiessler M and Schmeiser HH (2005a) Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH: cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer 113: 189-197. (Pubitemid 39628308)
49. Stiborova M, Frei E and Schmeiser HH (2008b) Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int 73: 1209-1211. (Pubitemid 351693150)
50. Stiborova M, Frei E, Sopko B, Sopkova K, Markova V, Lankova M etal. (2003) Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H: quinone oxidoreductase. Carcinogenesis 24: 1695-1703. (Pubitemid 37304677)
51. Stiborova M, Frei E, Sopko B, Wiessler M and Schmeiser HH (2002) Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23: 617-625. (Pubitemid 34498500)
52. Stiborova M, Frei E, Wiessler M and Schmeiser HH (2001 b) Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem Res Toxicol 14: 1128-1137. (Pubitemid 32800169)
53. Stiborova M, Hajek M, Frei E and Schmeiser HH (2001c) Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH: cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. Gen Physiol Biophys 20: 375-392. (Pubitemid 34196156)
54. Stiborova M, Hajek M, Vosmikova H, Frei E and Schmeiser HH (2001d) Isolation of DT-diaphorase [NAD(P)H dehydrogenase (quinone)] from rat liver cytosol: identification of new enzyme substrates, carcinogenic aristolochic acids. Collect Czech Chem Commun 66: 959-972.
55. Stiborova M, Mares J, Frei E, Arlt VM, Martinek V and Schmeiser HH.(2011) The human carcinogen aristolochic acid I is activated to form DNA adducts by human NAD(P)H: quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ. Mol. Mutagen 52: 448-459.
56. Stiborova M, Martinek V, Svobodova M, Sistkova J, Dvorak Z, Ulrichova J et al. (2010a) Mechanisms of the different DNA adduct forming potentials of the urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone. Chem Res Toxicol 23: 1192-1201.
57. Stiborova M, Moserova M, Mrazova B, Kotrbova V and Frei E. (2010b) Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney. Neuro Endocrinol. Lett. 31 (Suppl. 2): 26-35.
58. Stiborova M, Sopko B, Hodek P, Frei E, Schmeiser HH and Hudecek J (2005b) The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. Cancer Lett 229: 193-204. (Pubitemid 41429358)
59. Svobodova M, Martinkova M, Dracinska H, Frei E and Stiborova M (2009) Rat cytochromes P450 oxidize 2-nitrophenol, a human metabolite of carcinogenic 2-nitroanisole. Neuro Endocrinol Lett. 30 (Suppl. 1): 46-51.
60. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M et al. (1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341: 387-391. (Pubitemid 23048140)